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Abstract
Background and purpose: Magnitude of gluten-specific T-cell responses in coeliac 
disease (CD) might be dependent on HLA-DQ2 gene dose. We aimed to investigate 
the effects of HLA-DQB1*02 allele dose on clinical outcomes.
Methods: We reviewed the charts of all coeliac patients attending to three Hungarian 
university clinics after 1997 and included those patients, who (a) were diagnosed 
with CD, (b) underwent high-resolution HLA typing and (c) were ≥18 years at the time 
of data collection. HLA typing was performed to determine DQB1*02 allele dose. 
Patients were divided into risk groups by DQB1*02 allele dose, as follows: high-, in-
termediate- and low-risk groups corresponded to a double, single and zero doses, 
respectively. We used ANOVA and Pearson's chi-squared test to explore association 
between HLA risk and clinical variables.
Results: A total of 727 coeliac patients attended the clinics but only 105 (14.4%) pa-
tients were eligible for inclusion. High, intermediate and low HLA risk patients com-
prised 35.3%, 52.3% and 12.3% of the study population, respectively. Double dose of 
HLA-DQB1*02 was more frequent in patient with high tTGA level (>10 times the 
upper limit of normal; p = 0.045). Gene dose was not associated with younger age at 
diagnosis (p = 0.549), gender (p = 0.739), more severe diagnostic histology (p = 0.318), 
more frequent classical presentation (p = 0.846), anaemia (p = 0.611), metabolic bone 
disease (p = 0.374), dermatitis herpetiformis (p = 0.381) and autoimmune diseases 
(p = 0.837).
Conclusions: Our study shows a significant gene dose effect in terms of tTGA level at 
diagnosis, but no significant association between HLA-DQB1*02 allele dose and the 
clinical outcomes in CD.
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1  | INTRODUCTION
Coeliac disease (CD) is a highly heritable, immune-mediated sys-
temic disorder. The consumption of gluten-containing cereals trig-
gers a T-cell-mediated immune cascade resulting in impairment of 
small intestinal villous architecture and systemic manifestations. 
Nearly all (>99%) CD patients are positive for HLA-DQ2 and/or 
DQ8 (Abraham & Inouye, 2015; Korponay-Szabo, Troncone, & 
Discepolo, 2015).
DQ molecules are MHC class II proteins serving critical functions 
in the immune response to foreign antigens. Gliadin peptides are 
presented (with rare known exceptions) on DQ2 or DQ8 molecules. 
Tissue transglutaminase generates negatively charged peptide res-
idues in the deamidation of gliadin. Acting as high-affinity ligands, 
the peptide residues bind to HLA-DQ2 and DQ8 molecules of anti-
gen-presenting cells’ (APCs). Then, CD4+ T cells recognize this com-
plex, initiate cellular activation and trigger T-cell immune responses. 
Sequelae include severe tissue destruction accompanied by remod-
elling of small intestinal villous architecture (Kupfer & Jabri, 2012; 
Tjon, Van Bergen, & Koning, 2010).
The diagnosis of CD can be excluded by HLA typing because of 
its outstanding negative predictive value approaching 100% (Diaz-
Redondo, Miranda-Bautista, Garcia-Lledo, Gisbert, & Menchen, 
2015; Rubio-Tapia et al., 2013). The current paediatric guideline 
recommends HLA typing if patients are diagnosed without intesti-
nal biopsy (Husby et al., 2012). Although the diagnostic applicabil-
ity of HLA typing is clear, its role in risk stratification is still under 
debate. Homozygotes have the potential to synthesize the highest 
possible number of identical DQ2 molecules with effective antigen-
presentation properties. Unlike heterozygotes, who have multiple 
potential allele combinations, only some of them can present gliadin 
peptides (van Belzen et al., 2004). Accordingly, DQ2.5 homozygotes 
have a fivefold risk of CD, as compared to heterozygotes (Abraham 
& Inouye, 2015; Koning, 2012; Pietzak, Schofield, McGinniss, & 
Nakamura, 2009; Vader et al., 2003; van Belzen et al., 2004).
The way how HLA-DQ2 gene dose modifies clinical phenotype 
is unclear. High-risk DQ2.5 homozygous patients might have earlier 
disease onset with a more severe disease course as compared to 
those with other haplotypes (Agardh et al., 2015; Biagi et al., 2012; 
Congia et al., 1994; Demarchi et al., 1983; Jores et al., 2007; Karinen 
et al., 2006; Mubarak, Spierings, Wolters, Otten et al., 2013; Nenna 
et al., 2008; Zamani, Modares-Sadegi, Shirvani, Zamani, & Emami, 
2014; Zubillaga et al., 2002). However, many studies did not con-
firm this thesis (Akar, Yildiz, Sevinc, & Sokucu, 2015; Greco et al., 
1998; Maŕia Jesús et al., 2012; Murray et al., 2007; Mustalahti, 
Holopainen, Karell, Maki, & Partanen, 2002; Piccini et al., 2012; 
Ploski, Ek, Thorsby, & Sollid, 1993; Ros, Ros, Sanchez-Valverde, & 
Gimeno, 2010; Thomas et al., 2009; Vermeulen et al., 2009).
Early identification of high-risk patients would be of utmost im-
portance. A closer follow-up and a stricter gluten-free diet might help 
them to avoid the development of life-threatening complications 
(e.g., malignancies) (Megiorni & Pizzuti, 2012; Romanos et al., 2009). 
We aimed to investigate the association between HLA-DQB1*02 
allele dose with clinical parameters thereby attempting to define the 
role of HLA status in clinical risk stratification of CD patients.
2  | METHODS
2.1 | Patients
We included patients who were (a) diagnosed with CD by the cur-
rent guidelines in one of three Hungarian university clinics (1st 
Department of Internal Medicine, Division of Gastroenterology, 
University of Pécs, Pécs; 2nd Department of Internal Medicine, 
Semmelweis University, Budapest; 2nd Department of Internal 
Medicine, University of Debrecen, Debrecen), (b) underwent HLA 
typing after 2010 (when the current PCR-based method was in-
stalled) and (c) were ≥18 years at the time of data collection.
Clinical data were retrieved from medical files retrospectively by 
independent investigators, blinded to the HLA status of the patients. 
Since HLA genotyping is not mandatory in CD patients, it is not in-
corporated in our routine diagnostic management.
Scientific and Research Ethics Committee of the Medical 
Research Council has granted ethical approval of this research proj-
ect (45098–2/2016/EKU).
2.2 | HLA genotyping
Genomic DNA was isolated from peripheral venous blood (QIAamp 
DNA Blood Mini Kit). We used polymerase chain reaction with se-
quence-specific primers (PCR-SSP) and sequence-specific oligonucleo-
tide probes (PCR-SSO) on commercial kits (Inno-Train HLA Ready Gene 
PCR-SSP kit, Olerup PCR-SSO kit and SSO One Lambda Luminex kit) 
at Hungarian National Blood Transfusion Service (Budapest and Pécs) 
and at Department of Laboratory Medicine, Clinical Center, University 
of Debrecen (Debrecen). Both DQA1 and DQB1 alleles, including allele 
dose, were typed. Genotypes were determined by haplotypes.
The HLA risk categories corresponded to HLA-DQ2 gene dose, 
as follows: (a) high-risk HLA-DQ2.5 homozygotes (DQ2.5/DQ2.5) 
and compound heterozygotes (DQ2.5/DQ2.2) with a double dose 
of DQB1*02 alleles; (b) intermediate-risk HLA-DQ2.5 heterozygotes 
(DQ2.5/DQX) and HLA-DQ2 in trans (DQ2.2/DQ7) with a single 
dose of DQB1*02 allele; and (c) low-risk HLA groups (HLA-DQ8/
DQX, HLA-DQ2.2/DQX, X corresponded to any alleles except for 
DQ2.5) with zero doses of DQB1*02 allele.
2.3 | Clinical features
Age at diagnosis corresponded to the date of definite diagnosis 
when gluten-free diet was introduced. We defined the clinical pres-
entation as per Oslo criteria as classical CD (with malabsorptive 
syndrome, e.g., diarrhoea and weight loss, irrespective of extraintes-
tinal manifestations) and non-classical CD (without malabsorptive 
syndrome e.g., atypical gastrointestinal symptoms, extraintestinal 
manifestations) (Ludvigsson et al., 2013). We classified diagnostic 
small intestinal histology according to Corazza-Villanacci (Corazza & 
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Villanacci, 2005). Levels of tissue transglutaminase antibody (tTGA) 
were measured at diagnosis with ELISA. Positive tTG serology was 
further divided into two groups: patients with high and low titre 
levels were defined as >10 times or ˂10 times of the upper limit of 
normal (ULN), respectively. Haemoglobin levels <130 and <120 g/L 
indicated anaemia in men and women, respectively. Metabolic bone 
disease (including osteopenia and osteoporosis) was defined as 
measuring a T-score <−1.0 standard deviation by dual-energy X-ray 
absorptiometry (DEXA). Concurrent autoimmune diseases, malig-
nancies and dermatitis herpetiformis were assessed, as well.
2.4 | Statistical analysis
We performed Pearson's chi-squared test to analyse the association 
between HLA risk and categorical variables and one-way ANOVA 
to compare age at diagnosis across HLA risk groups. p < 0.05 indi-
cated the rejection of the null hypothesis. Statistical analysis was 
carried out by IBM SPSS Statistics v 20.0 (IBM's Corporate, New 
York, USA).
3  | RESULTS
3.1 | Demography
A total of 727 coeliac patients attended the clinics between 
November 1997 and May 2016, of them 105 (14.4%) were eligible 
for inclusion in the study. High, intermediate and low HLA risk pa-
tients comprised 35.3%, 52.3% and 12.3% of the study population, 
respectively. Fifteen patients (14.3%) were diagnosed in childhood 
(<18 years), and another 90 (85.7%) in adulthood (≥18 years). We ob-
served female predominance in our cohort (73 female vs. 32 male 
patients) without significant gender differences between the HLA 
risk groups (p = 0.739).
3.2 | Age, clinical presentation, serology and 
histology at diagnosis
Mean age at diagnosis was 31.2 years (SD: 15.747, range: 0.5–
78 years). Age at diagnosis did not differ significantly between the 
risk groups (p = 0.549).
Forty-five of the 105 patients (42.9%) had classical CD. We failed 
to prove a significant association between HLA risk and clinical pre-
sentation (p = 0.846): 15 of 37, 25 of 55 and 5 of 13 patients had 
classical CD in the high, intermediate and low HLA risk groups, re-
spectively (Table 1).
tTGA was measured in 70 of 105 patients at diagnosis, nine 
of them (12.9%) were seronegative (3, 2 and 4 cases with zero, 
single and double dose of HLA-DQB1, respectively). In the 
other 35 cases, the serological diagnosis was based on endo-
mysium antibody positivity. Of the tTGA-positive patients, 34 
had a low level of tTGA (2, 17 and 15 cases with zero, single 
and double dose of HLA-DQB1, respectively) and another 27 
TA B L E  1   Risk stratification and clinical phenotype
Locus B1 PCR1 Locus B1 PCR2 B1*02 allele dose HLA genotype Classical phenotype (n) Non‐classical phenotype (n)
High risk 15 22
B1*0201 B1*0201 Double DQ2.5/DQ2.5 8 16
B1*0201 B1*0202 Double DQ2.5/DQ2.2 7 6
Intermediate risk 25 30
B1*0201 B1*05 Single DQ2.5/DQ5 5 9
B1*0201 B1*06 Single DQ2.5/DQ6 3 7
B1*0201 B1*0301 Single DQ2.5/DQ7 9 6
B1*0201 B1*0302 Single DQ2.5/DQ8 2 4
B1*0201 B1*0303 Single DQ2.5/DQ9 1 1
B1*0202 B1*0301 Single DQ2.2/DQ7 5 3
Low risk 5 8
B1*0202 B1*0202 Zero DQ2.2/DQ2.2 0 0
B1*0202 B1*04 Zero DQ2.2/DQ4 0 1
B1*0202 B1*06 Zero DQ2.2/DQ5 1 0
B1*0202 B1*0302 Zero DQ2.2/DQ8 2 1
B1*0302 B1*0302 Zero DQ8/DQ8 0 1
B1*0302 B1*04 Zero DQ8/DQ4 0 1
B1*0302 B1*06 Zero DQ8/DQ6 0 1
B1*0302 B1*0301 Zero DQ8/DQ7 2 3
In the left foremost column, 3 groups are highlighted with bold (High risk, Intermediate risk, and Low risk), rows below indicate those alleles belonging 
to these groups. Bold numbers indicate the total number of patients within these groups dichotomized into classical and non-classical phenotypes.
HLA: human leucocyte antigen; PCR: polymerase chain reaction.
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patients had high level of tTGA. In the comparison of seropos-
itive patients with the double dose to those with the single 
dose, higher levels of tTGA were more frequent as in the former 
group (p = 0.045).
We detected no significant association between diagnostic his-
tological severity and HLA risk (p = 0.318), even if we included only 
patients diagnosed in adulthood.
3.3 | Anaemia and metabolic bone disease
Gene dose effect seems to be unimportant in the development of 
anaemia (p = 0.611) and metabolic bone disease (p = 0.374) either 
in the whole study population or in the subgroup of patients diag-
nosed in adulthood. However, 14, and 43 of 105 cases did not have 
available baseline haemoglobin levels and DEXA scores. Forty of 91 
patients (44.0%) had anaemia while 38 of 62 patients (61.3%) had 
metabolic bone disease.
3.4 | Concomitant autoimmune diseases
Twelve patients (11.4%) had dermatitis herpetiformis, all of them 
were in the high or intermediate HLA risk groups, and nearly half 
of them had classical CD. The frequency of dermatitis herpetiformis 
was independent of HLA status (p = 0.381). Interestingly, DH was di-
agnosed exclusively in high-risk DQ2.5 homozygotes (five patients) 
or intermediate-risk patients (seven patients).
Twenty-eight patients (26.7%), with a prominent female pre-
dominance of 3:1, had a concurrent autoimmune disease. The most 
frequent autoimmune disease was autoimmune thyroid disease (15 
patients). Seven patients had inflammatory bowel disease (five cases 
TA B L E  2   Gene dose and clinical parameters in CD patients with autoimmune disease(s)
Patients Gender
Age at diagnosis 
(years)
HLA 
genotype
B1*02 allele 
dose Clinical phenotype Autoimmune disease
1 Female 41 DQ2.5/DQ2.5 Double Classical Autoimmune thyroid disease
2 Male 18 DQ2.5/DQ2.5 Double Classical Ulcerative colitis
3 Female 4 DQ2.5/DQ7 single classical Crohn's disease
4 Male 25 DQ2.5/DQ5 Single Classical Crohn's disease
5 Male 28 DQ2.5/DQ7 Single Non-classical Autoimmune thyroid disease
6 Female 20 DQ2.5/DQ2.5 Double Classical Autoimmune thyroid disease
7 Female 36 DQ2.2/DQ7 Single Classical Ulcerative colitis
8 Female 26 DQ2.5/DQ8 Single Non-classical Alopecia areata
9 Female 56 DQ2.5/DQ5 Single Classical Autoimmune thyroid disease
10 Female 59 DQ2.5/DQ5 Single Classical Sarcoidosis
11 Female 2 DQ2.5/DQ7 Single Classical Autoimmune thyroid disease
12 Female 27 DQ2.5/DQ7 Single Non-classical Autoimmune thyroid disease
13 Female 24 DQ2.5/DQ2.5 Double Classical Autoimmune thyroid disease
14 Female 17 DQ2.5/DQ2.5 Double Non-classical Autoimmune thyroid disease
15 Female 31 DQ2.5/DQ5 Single Non-classical Autoimmune thyroid disease
16 Female 51 DQ2.5/DQ5 Single Non-classical Autoimmune thyroid disease
17 Female 35 DQ2.5/DQ5 Single Non-classical Lichen ruber planus
18 Male 10 DQ8/DQ7 Zero Non-classical Alopecia areata
19 Female 41 DQ2.2/DQ5 Zero Classical Autoimmune liver disease
20 Female 36 DQ2.5/DQ2.2 Double Non-classical Rheumatoid arthritis, myasthe-
nia gravis
21 Male 43 DQ2.5/DQ7 Single Classical Autoimmune thyroid disease
22 Female 23 DQ2.5/DQ2.5 Double Non-classical Autoimmune thyroid disease
23 Female 46 DQ2.5/DQ2.2 Double Non-classical Autoimmune thyroid disease
24 Female 62 DQ2.5/DQ5 Single Classical Autoimmune thyroid disease, 
ulcerative colitis
25 Male 37 DQ8/DQ7 Zero Non-classical Autoimmune thyroid disease
26 Female 29 DQ2.5/DQ2.5 Double Non-classical Psoriasis
27 Female 14 DQ2.5/DQ6 Single Classical Ulcerative colitis
28 Male 30 DQ2.5/DQ6 Single Classical Ulcerative colitis, sacroileitis
HLA: human leucocyte antigen.
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of ulcerative colitis and two cases of Crohn's disease), two patients 
had alopecia areata, and there were isolated cases of rheumatoid ar-
thritis, myasthenia gravis, lichen ruber planus, sarcoidosis, psoriasis, 
sacroileitis and autoimmune liver disease. Type 1 diabetes mellitus 
was not observed in the study population. Autoimmunity was inde-
pendent of HLA status (p = 0.837), as shown in Table 2.
3.5 | Malignant tumours
Malignant tumours were diagnosed in three patients: a female pa-
tient (DQ2.2/DQ7 heterozygote) developed malignant melanoma 
at the age of 38 years (CD was diagnosed at the age of 36 years), 
another female patient (DQ2.5 homozygote) died of pancreatic ad-
enocarcinoma at the age of 75 years (CD was diagnosed at the age 
of 59 years), and a male patient (DQ2.5 homozygote) had lung ad-
enocarcinoma at the age of 55 years (CD was diagnosed at the age 
of 46 years). Here, the low case number did not allow us to perform 
statistical analysis.
Refractory CD did not occur in the study population.
4  | DISCUSSION
Although the theoretical background suggests a significant gene 
dose effect in CD, we proved only association between HLA-DQ2 
gene dose and tTGA level but not in connection with the clinical 
features.
The influence of DQ2 gene dose on clinical phenotype is rather 
vague, lack of consensus on risk stratification systems might contrib-
ute to the contradictory results. It is pervasive that DQ2.5 or DQ2 
homozygosis confer the highest risk of adverse outcomes, but au-
thors are divided in terms of low-risk categories (Abraham & Inouye, 
2015; Delgado et al., 2014; Gudjonsdottir et al., 2009; Koning, 2012; 
Margaritte-Jeannin et al., 2004; Medrano et al., 2012; Megiorni 
& Pizzuti, 2012; Mubarak, Spierings, Wolters, Otten et al., 2013; 
Nenna et al., 2008; Piccini et al., 2012; Romanos et al., 2009; Ros et 
al., 2010; Rostami-Nejad et al., 2014; Vader et al., 2003; van Belzen 
et al., 2004; Vermeulen et al., 2009). In accordance, we stratified risk 
by the number of DQB1*02 alleles (i.e., gene dose) so that patients 
with DQ2.5/2.5 and DQ2.5/2.2 represented the high-risk category 
(Table 1). As expected, all of our patients were positive for HLA DQ2 
and/or DQ8. Although double-dose DQB1*02 is more frequent 
in this population than that of reported earlier (35.2% vs. 19.7% 
and 21.3%) (Piccini et al., 2012; Thomas et al., 2009), DQ2.5/2.5 
frequency proved as high as in a previous work (22.9% vs. 19.2%) 
(Stankovic et al., 2014).
Lack of gene dose effect was reported frequently, for exam-
ple in terms of age at presentation of first symptoms (Greco et al., 
1998; Vermeulen et al., 2009); age (Akar et al., 2015; Greco et al., 
1998; Murray et al., 2007; Mustalahti et al., 2002; Thomas et al., 
2009), histological damage (Murray et al., 2007; Thomas et al., 2009; 
Vermeulen et al., 2009) and clinical symptoms (Akar et al., 2015; 
Greco et al., 1998; Murray et al., 2007; Vermeulen et al., 2009) at 
diagnosis; anaemia or haemoglobin levels (Akar et al., 2015; Thomas 
et al., 2009); coeliac-specific serology (Murray et al., 2007); iron, 
mineral and vitamin deficiencies (Akar et al., 2015; Thomas et al., 
2009); metabolic bone disease (Thomas et al., 2009) and autoimmu-
nity (Malamut et al., 2012). On the contrary, studies reported sig-
nificant gene dose effect in terms of, for example age (Liu, Lee, & 
Agardh, 2014; Nenna et al., 2008; Ploski et al., 1993; Zubillaga et 
al., 2002), clinical presentation (Congia et al., 1994; Demarchi et al., 
1983; Karinen et al., 2006; Nenna et al., 2008; Zubillaga et al., 2002) 
and histological damage (Jores et al., 2007; Karinen et al., 2006) at 
diagnosis; coeliac-specific serology (Agardh et al., 2015; Nenna et 
al., 2008; Thomas et al., 2009), anaemia (Karinen et al., 2006), au-
toimmune diseases (Lionetti et al., 2014; Liu et al., 2014) and malig-
nant tumours (Al-Toma et al., 2006; Biagi et al., 2014; Malamut et 
al., 2012).
Gene dose effect might determine magnitude of T-cell re-
sponses. APCs extracted from DQ2.5 homozygotes induced more 
prominent T-cell proliferation and interferon γ production, as 
compared to HLA-DQ2.5/DQX heterozygotes (X corresponded to 
any haplotypes except for DQ2.5). Taken together, the number of 
HLA-DQ2.5 molecules on APCs determines the magnitude of T-cell 
responses (Vader et al., 2003), in other words “quantity matters” 
(Koning, 2012). Enhanced antibody response, observed in our study 
in homozygotes as well, seems to support this theory.
Among alleles encoding DQ2.5, the number of B1*02 is deci-
sive; the presence of double-dose A1*05 is not essential to trigger 
full-strength immune responses (Karinen et al., 2006; Medrano et 
al., 2012; Megiorni et al., 2009; Piccini et al., 2012; Pisapia et al., 
2016; van Belzen et al., 2004). The most prominent response is ex-
pected in DQ2 homozygotes (including DQ2.5/DQ2.5) and in com-
pound heterozygotes (DQ2.5/DQ2.2), who have a double dose of 
B1*0201 (Abraham & Inouye, 2015; Demarchi et al., 1983; Kupfer 
& Jabri, 2012; Margaritte-Jeannin et al., 2004; Pietzak et al., 2009; 
Rostami-Nejad et al., 2014). DQ2.5/DQX heterozygotes and those 
with DQ2.2/DQ7.5 genotype (so-called DQ2.5 trans) have a single 
dose of B1*02 allele (Korponay-Szabo et al., 2015; Mearin et al., 
1983; Mubarak, Spierings, Wolters, van Hoogstraten et al., 2013). 
Here, the chance of synthesizing (high affinity) DQ2.5 molecules is 
only 25%; therefore, this haplotype is deemed to be an intermedi-
ate-risk one (van Belzen et al., 2004; Vader et al., 2003). Other HLA 
haplotypes, not producing functioning DQ2 molecules, are accom-
panied by low risk of CD.
On the contrary, a few findings oppose gene dose effect. Equal 
magnitude of specific T-cell responses characterizes homo- and het-
erozygotes. In addition to heterozygotes, the amount of DQA1*05 
and DQB1*02 mRNS exceeded the expected 50% of those mea-
sured in homozygotes (Pisapia et al., 2016).
Coeliac disease is strongly HLA-linked but the effect of non-
HLA loci (not taken into account in this study) can outweigh that 
of HLA. In a study, HLA risk stratification was complemented with 
10 non-HLA loci which resulted in the allocation of 10% of study 
population from the moderate- to the high-risk group (Romanos et 
al., 2009). Besides, nongenetic (environmental) factors contribute to 
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CD phenotype (Greco et al., 1998; Gudjonsdottir et al., 2009; Piccini 
et al., 2012; Vermeulen et al., 2009).
Taken together, it is possible that genetic (non-HLA) and envi-
ronmental factors masked a significant gene dose effect. However, 
the retrospective design (missing data) restricts the validity of our 
findings. The low case numbers and event rates raise concerns 
about the occurrence of β-type error. Only a small minority (14.4%) 
of patients underwent HLA typing because it is not mandatory at 
diagnosis (Husby et al., 2012). The low case number did not allow us 
to perform separate analysis on patients with childhood diagnosis. 
Some clinical features, especially symptoms, are difficult to be cate-
gorized without bias; therefore, we used the classical/non-classical 
distinction (as per the Oslo classification) to decrease risk of bias 
(Ludvigsson et al., 2013).
The HLA status is an unalterable, lifelong persistent marker, not 
influenced by age, gluten intake or environment. The diagnostic yield 
of HLA typing is clear, whereas the usefulness of HLA-based risk 
stratification has remained questionable. Our study showed that pa-
tients with a double dose of HLA-DQB1*02 have higher tTGA titre 
at diagnosis but we failed to prove an association between HLA-DQ 
genotypes and the clinical features, namely age at diagnosis, clini-
cal presentation (classical vs. non-classical CD), frequency of anae-
mia, dermatitis herpetiformis, metabolic bone disease, autoimmune 
diseases and malignancies. Large number, prospective studies are 
needed to clarify the role of HLA risk stratification in clinical practice.
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